PNC FINANCIAL SERVICES GROUP, INC. - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.

Quarter-by-quarter ownership
PNC FINANCIAL SERVICES GROUP, INC. ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$16,827
-15.2%
472
+9.8%
0.00%
Q2 2023$19,836
+870.5%
430
+743.1%
0.00%
Q1 2023$2,044
-80.6%
51
-77.5%
0.00%
Q4 2022$10,518
+50.3%
227
+23.4%
0.00%
Q3 2022$7,000
-41.7%
184
-9.8%
0.00%
Q2 2022$12,000
-40.0%
204
-29.7%
0.00%
Q1 2022$20,000
+100.0%
290
+130.2%
0.00%
Q4 2021$10,000
-33.3%
126
-25.4%
0.00%
Q3 2021$15,000
+7.1%
169
+22.5%
0.00%
Q2 2021$14,000
+55.6%
138
+81.6%
0.00%
Q1 2021$9,000
+50.0%
76
+65.2%
0.00%
Q4 2020$6,000
-33.3%
46
-63.5%
0.00%
Q3 2020$9,000
+28.6%
126
+40.0%
0.00%
Q2 2020$7,000
-99.1%
90
-99.5%
0.00%
-100.0%
Q3 2019$809,000
-52.8%
18,921
-29.9%
0.00%
-50.0%
Q2 2019$1,715,000
+85650.0%
26,990
+141952.6%
0.00%
Q1 2019$2,00019
+18.8%
0.00%
Q4 2018$0
-100.0%
160.0%0.00%
Q3 2018$2,0000.0%16
-68.6%
0.00%
Q4 2017$2,000
-80.0%
51
-74.5%
0.00%
Q2 2016$10,000
-23.1%
200
-3.4%
0.00%
Q1 2016$13,000
-50.0%
207
-12.7%
0.00%
Q4 2015$26,000
-38.1%
237
-45.3%
0.00%
Q3 2015$42,000
+61.5%
433
+69.8%
0.00%
Q2 2015$26,000
+271.4%
255
+116.1%
0.00%
Q1 2015$7,0001180.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2023
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 497,899$31,617,0003.20%
HIGHLINE CAPITAL MANAGEMENT, L.P. 390,453$24,794,0001.81%
First Light Asset Management, LLC 180,017$11,431,0001.59%
Rock Springs Capital Management LP 580,000$36,830,0001.33%
Capital Impact Advisors, LLC 36,165$2,244,0000.82%
SECTOR GAMMA AS 79,653$5,058,0000.81%
Verity Asset Management, Inc. 7,193$457,0000.51%
Opus Point Partners Management, LLC 5,064$322,0000.48%
Capital International Sarl 52,000$3,302,0000.46%
PACIFIC VIEW ASSET MANAGEMENT, LLC 6,216$394,0000.43%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders